OSTX OS Therapies Incorporated
Financings ·
OS Therapies raised $7.2 million gross in the first closing of a warrant inducement, but the holders who exercised received new warrants for the same number of shares at $1.40, and the company reported only $205,035 in cash at June 30, 2026.
The first closing on August 10, 2026 covered $5,000,000 of units, including a bridge note conversion, and the second tranche is optional for each purchaser.
The company calls it a line of credit backed by UK tax credits. It drew $1.6 million first, mainly for OST-HER2 manufacturing.
OS Therapies will miss the May 15, 2026 deadline for its first-quarter 10-Q and says it expects to file within the five-day extension. The filing comes from a company whose annual report, filed March 31, 2026, carries a going-concern warning and reports $269,830 of cash at year-end.
OS Therapies could not file its quarterly report for the period ended June 30, 2025 by its August 14, 2025 due date. Its last annual report carried an auditor's going concern warning and showed $5,533,527 of cash at the end of 2024.
OS Therapies says it needs more time to finish its financial statement close for the quarter ended June 30, 2025, and expects to file within the five-day extension.
OS Therapies says the purchase adds three clinical-stage and eight preclinical listeria-based cancer immunotherapy candidates, but the release gives neither the price nor the terms.
OS Therapies is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for osteosarcoma and other solid tumors. Its mission is to address the need for new treatments for cancers of the bone in children and young adults. Its lead product candidate, OST-HER2 (also known as OST31-164), is a cancer immunotherapy that aims to produce a cellular immune response against the HER2 antigen. It is an off-the-shelf immunotherapy made from a genetically weakened and modified strain of Listeria monocytogenes that expresses HER2 peptides. A clinical study in patients after resection of recurrent osteosarcoma enrolled 41 patients, and the company announced in the first quarter of 2025 that its Phase IIb trial achieved its primary endpoint. In October 2025 it reported final two-year overall survival data, in which 75% (27 of 36 evaluable patients) of OST-HER2-treated patients reached two-year overall survival, compared with 40% in historical control patients. The company submitted the non-clinical and CMC modules of a Biologics License Application for OST-HER2 to the FDA at the end of January 2026. It also owns rights to an OST-Tunable Drug Conjugate platform, which is in preclinical development.
| Product or program | What it is | Stage |
|---|---|---|
| OST-HER2 (OST31-164) | Listeria-based cancer immunotherapy expressing HER2 peptides for osteosarcoma | Phase IIb met primary endpoint; BLA non-clinical and CMC modules submitted January 2026 |
| OST-tADC | Tunable antibody-drug conjugate platform with pH-sensitive SiLinkers | Preclinical development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $16.4 million | $2.8 million |
| Net income (loss) | -$28.8 million | -$8.9 million |
| Cash from operations | -$14.2 million | -$7.3 million |
| Cash and equivalents | $269,830 | $5.5 million |
Our latest story on this, dated May 15, 2026: "OS Therapies files NT 10-Q, says first-quarter report will be late after slower financial close". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 10, 2026: "OS Therapies sells up to $10,000,000 of senior secured convertible notes". The story links the filing or release it is based on. Read the story.
OS Therapies Incorporated trades under the ticker OSTX on AMEX.
OS Therapies Incorporated is listed on AMEX.
The SEC Central Index Key (CIK) for OS Therapies Incorporated is 1795091. Its filings are on SEC EDGAR.
46,125,825 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Our directory records OS Therapies Incorporated under United States.
Our directory classifies OS Therapies Incorporated as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for OS Therapies Incorporated is US68764Y2072.
aibio.space lists OS Therapies Incorporated among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
OS Therapies is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for osteosarcoma and other solid tumors. Its mission is to address the need for new treatments for cancers of the bone in children and young adults.
OST-HER2 (OST31-164): Listeria-based cancer immunotherapy expressing HER2 peptides for osteosarcoma Stage: Phase IIb met primary endpoint; BLA non-clinical and CMC modules submitted January 2026.
OST-tADC: Tunable antibody-drug conjugate platform with pH-sensitive SiLinkers Stage: Preclinical development.
OS Therapies Incorporated reported a net loss of $28.8 million for the fiscal year ended Dec 31, 2025, and used $14.2 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,5.02,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B7. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 424B7. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B7. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio